Strata Critical Medical, Inc.
SRTA Nasdaq· Services-Health Services
Last close · Oct 27, 2026
$4.72
KIRA · Stoqly’s AI analyst, in plain words
- Strata Critical Medical, Inc. had $197M of revenue in fiscal 2025, up 34.3% on the year before.
- Its operating margin was −11.3%, up 4.0 pts: of every 100 in sales, about −11 is left after running the business.
- Strata Critical Medical, Inc. made $41.3M of net profit in fiscal 2025.
- Free cash flow was −$58.5M in fiscal 2025, −29.7% of revenue.
- Strata Critical Medical, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 5.9%.
Market cap
$407M
P/E
9.4x
Revenue
$197M
Net income
$41.3M
Free cash flow
−$58.5M
Operating margin
−11.3%
Strata Critical Medical, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+34.3%
Yes. Sales grew 34.3% last year.
Does it make a profit?
21.0%
Yes. It keeps 21.0% of every sale as profit.
Does profit turn into cash?
−29.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
9.4x
One share costs 9.4 times its yearly profit per share.
What Strata Critical Medical, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Strata Critical Medical, Inc.
- CIK
- 0001779128
Strata Critical Medical, Inc. · SRTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $50.5M | — | $225M | $147M | $197M |
| Revenue growth | — | — | — | −34.8% | 34.3% |
| Net interest income | $0.5M | — | $8.4M | $7.2M | — |
| Gross margin | 20.8% | — | 18.7% | 20.2% | 20.9% |
| Operating margin | −47.7% | — | −30.3% | −15.3% | −11.3% |
| Net income | −$40.1M | — | −$56.1M | −$27.3M | $41.3M |
| Net margin | −79.3% | — | −24.9% | −18.6% | 21.0% |
| Diluted EPS | −$0.93 | — | −$0.76 | −$0.35 | $0.50 |
| Cash | |||||
| Cash from operations | −$15.6M | — | −$32.3M | −$2.5M | −$48.9M |
| Capital expenditure | $0.3M | — | $2.1M | $30.9M | $9.6M |
| Free cash flow | −$15.9M | — | −$34.5M | −$33.4M | −$58.5M |
| FCF margin | −31.5% | — | −15.3% | −22.7% | −29.7% |
| Share buybacks | — | — | $0.0M | $0.2M | $0.0M |
| Share count change | — | — | — | 5.4% | 5.9% |
| Debt and strength | |||||
| Cash and short-term investments | $304M | $192M | $166M | $127M | $61.2M |
| Debt incl. finance leases | — | $0.0M | — | — | — |
| Shareholders' equity | $291M | $274M | $234M | $222M | $279M |
| Current ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
| Returns and quality | |||||
| Return on equity | −13.8% | — | −22.0% | −12.0% | 16.5% |
| Return on tangible equity | −15.1% | — | −28.0% | −13.8% | 28.8% |
| Piotroski F-score | — | — | — | 4 | 4 |
| Altman Z'' | 10.5 | — | 4.5 | 7.3 | 6.5 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.9M
5 insiders
Of sales under plans
41%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Strata Critical Medical, Inc. · SRTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.72 a share, the company is worth $407M: 9.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001779128). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.